1084P - Prognostic impact of the Neutrophil-to-Lymphocyte Ratio (NLR) on overall survival in patients treated with chemoradiotherapy for head and neck cancer

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancer in Adolescents
Head and Neck Cancers
Surgery and/or Radiotherapy of Cancer
Presenter Samira Makhloufi
Citation Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374
Authors S. Makhloufi1, G. Lefebvre1, I. Sakji2, F. Feutry2, T. Leroy3, N. Penel1, B. Coche3, J. Fourquet3, F. Ghestem1, M. Julieron4, D. Chevalier5, E. Tresch6
  • 1Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 2Pharmacy, Centre Oscar Lambret, 59020 - Lille/FR
  • 3Academic Radiation Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 4Head And Neck Surgery, Centre Oscar Lambret, 59020 - Lille/FR
  • 5Head And Neck Surgery, University Hospital, Lille/FR
  • 6Statistics Unit, Centre Oscar Lambret, 59020 - Lille/FR

Abstract

Background

The neutrophil-to-lymphocyte ratio (NLR), a marker of the systemic inflammatory response, has been reported to have prognostic value in different cancer settings. In this study we aimed to assess the prognostic impact of NLR in a cohort of patients with head and neck cancers.

Methods

Patients with head and neck cancer treated with concurrent chemo-radiotherapy (Cisplatin) between 01/2013 and 12/2015 were included in this study. NLR was analyzed as a continuous variable and as dichotomous variable (≤ 5 vs. > 5). The primary end point was overall survival (OS). Progression free survival (PFS) was the secondary endpoint. Univariate analysis was used to identify associations and to select variables included in multivariate Cox regression analysis to determine prognostic value.

Results

146 patients (132 squamous cell carcinomas (SCC), 10 undifferencied nasopharyngeal carcinomas (UCNT) and 4 neuroendocrine carcinomas) were included in this analysis. The median follow up was 20.6 months (2.4-37.0 months). 1-year and 2-year OS were 87.1% and 82.3%, respectively.1-year and 2-year PFS were 75.9% and 68.0%, respectively. On univariate analysis, OS significantly differed between groups NLR ≤ 5 vs. > 5. In the overall population (OP) (HR: 2.6; IC95%: [1,05-6,53]; p = 0036) and in non-oropharyngeal subpopulation (HR: 3.67; IC95%: [1,19-11,4]; p = 0,016) but not in the oropharyngeal subpopulation (p = 0,51). In multivariate analysis NLR >5 was significantly associated with a poorer OS in the OP (HR: 2.89; IC95%: [1,14-7,33]; p = 0.025) and in non-oropharyngeal subpopulation (HR: 4.53; IC95%: [1,34-13,5]; p = 0.014). Body Mass Index (BMI)

Conclusions

In this cohort of patients treated with chemo-radiotherapy for head and neck cancer, pre-treatment NLR >5 was predictive of shorter overall survival. Further prospective clinical investigations are required to confirm these results and determine the clinical applicability as prognostic factor.

Clinical trial identification

Legal entity responsible for the study

Centre Oscar Lambret

Funding

None

Disclosure

All authors have declared no conflicts of interest.